Year: 2025

Harvia Plc, Stock Exchange Release, New performance period for the Long-term Performance Share Plan, 11 March 2025 at 2:00 p.m EET The Board of Directors of Harvia Plc have decided on a new performance period for the Long-term Performance Share Plan for the key employees The Board of Directors of Harvia Plc has decided on March 10th, 2025 to continue the Long-term Performance Share Plan for the management team and other key employees for the performance period 2025-2027. The plan will form a part of Harvia Plc’s remuneration program for its key employees, and the aim of the Plan is to support the implementation of the company’s strategy, to align the objectives of key employees with the shareholders to increase the value of the company, to improve the performance of the company, and to retain key employees. In the performance period...

LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 25, 2025, after market close. The Company will host a conference call to discuss the results at 5:00 p.m. Eastern Time. Participants can find the live webcast here or on the Glass House Brands website at https://glasshousebrands.com/news-events/events-and-webcasts/. The webcast will be archived for approximately 30 days. Participants interested in dialing in can call 1.800.715.9871 or +1.646.307.1963 and...

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website. About X4 PharmaceuticalsX4 is delivering...

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security, and global markets, today announced the award of the Short/Medium Range Sub-Orbital Vehicle (SSOV) II contract as a partner to Corvid Technologies, LLC. The contract, awarded by the Naval Surface Warfare Center, Port Hueneme, White Sands Detachment, will encompass the design, manufacture, and delivery of short- and medium-range suborbital vehicles, including provision of ground test hardware, special test equipment, materials, engineering, and launch support services. The contract includes options which, if exercised, bring the potential subcontract value to greater than $50 million. Josh Peterson, Senior Vice President at Kratos Defense & Rocket Support Services,...

– Topline data expected as early as mid-2025 – SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. “We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improved immune responses of our second-generation constructs,” said Steven Lo, Chief Executive Officer of Vaxart. “As norovirus continues to spread across the United States and globally, it has never been more important to address this urgent public health need. With no currently approved vaccines against norovirus, we are committed...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the clearance of its Investigational New Drug (IND) application for TVB-3567, the Company’s second fatty acid synthase (FASN) inhibitor. TVB-3567 is a potent and selective small molecule FASN inhibitor, planned to enter clinical development for the treatment of acne. The IND with the U.S. Food and Drug Administration’s Division of Dermatology and Dentistry allows the Company to initiate a first-in-human Phase 1 clinical trial of TVB-3567, planned in 2025. “The...

BUFFALO, N.Y., March 11, 2025 (GLOBE NEWSWIRE) — ACV (Nasdaq: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced today that it will transfer the listing and trading of its common stock to the New York Stock Exchange (“NYSE”) from the Nasdaq Stock Market LLC (“Nasdaq”). ACV’s common stock is expected to begin trading on the NYSE on March 24, 2025, and will continue to be traded under its current ticker symbol “ACVA.” ACV’s common stock is expected to continue to trade on Nasdaq until the close of the market on March 21, 2025. “We are excited to announce the transfer of our company’s stock listing to the NYSE, which represents another step in our journey as a public company,” said Bill Zerella, CFO of ACV. “We believe the NYSE’s market infrastructure and global...

Brera Holdings Executive Chairman Daniel McClory and Juve Stabia President Andrea Langella, with Brera investors, at the Juve Stabia – Cittadella matchBrera Holdings Executive Chairman Daniel McClory and Juve Stabia President Andrea Langella, with Brera investors, at the Juve Stabia – Cittadella matchBrera investors and partners on the famous Gulf of Naples, next to the famous Castel dell’Ovo of NaplesBrera investors and partners on the famous Gulf of Naples, next to the famous Castel dell’Ovo of NaplesA visit to Juve Stabia academy at Cercola Training Center in Naples, with U-13s picturedA visit to Juve Stabia academy at Cercola Training Center in Naples, with U-13s picturedDublin, Ireland and Naples, Italy, March 11, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera” or the “Company”) (Nasdaq:...

Measured Hiring Strategy to Support Operational Excellence and Service Capabilities WALNUT, CA, March 11, 2025 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced workforce expansion, with employee headcount increasing by 20% over the past 20 months. Armlogi has adopted a disciplined approach to scaling its operations, as it endeavors to maintain service quality.  Since July 2023, Armlogi grew from 173 employees to 208 employees as of March 2025. This measured expansion aligns with increasing client demand and the Company’s enhanced service offerings. “We believe that our workforce development strategy...

MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights:CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025. New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics. Full year operating cost reduction of $5.9 million, or 26%, compared to the prior year. Revenue of $2.3 million, a 9% decrease compared to the prior year quarter. Consumables utilization growth of 21% compared to the prior year quarter. Critical Care customer category revenue...